AABB's cell manufacturing facility produced tisagenlecleucel, the first genetically modified cell therapy product approved by the FDA.
Published
Signal category
Products & Services
Quote
“His cell manufacturing facility produced tisagenlecleucel, the first genetically modified cell therapy product approved by the FDA.”
— AABB team
Company
AABB
Improving lives by making transfusion medicine and biotherapies safe, available, and effective worldwide.
- Industry
- Non-profit Organizations
- Location
- N BETHESDA, US
- Company size
- 721 employees
Follow this page for information on AABB initiatives and job opportunities. Join the AABB LinkedIn group to connect with like-minded professionals. AABB is an international, not-for-profit association representing individuals and institutions involved in the fields of transfusion medicine and cellular therapies. The association is committed to improving health through the development and delivery of standards, accreditation and educational programs that focus on optimizing patient and donor care and safety. AABB membership includes physicians, nurses, scientists, researchers, administrators, medical technologists and other health care providers. AABB members are located in more than 80 countries and AABB accredits institutions in more than 50 countries. Learn more about AABB at www.aabb.org.
Founded 1947